Loading
The randomised trial that made treating a handful of metastases with pinpoint radiotherapy respectable: survival was longer with SABR, and at five years more than twice as many patients were alive.
Ninety-nine patients with one to five metastases were randomised between palliative standard of care and standard of care plus stereotactic ablative radiotherapy to all sites. The 2019 Lancet report showed longer overall survival with SABR; the 2020 long-term update reported five-year overall survival of 42.3 percent with SABR against 17.7 percent with standard care. Grade 5 toxicity occurred in the SABR arm, and the phase 3 successors SABR-COMET-3 and SABR-COMET-10 are testing the approach in one to three and four to ten metastases.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT01446744 with the most citations, so it is the natural first reading for anyone following the trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Prostate cancer and the tag owner-request.
Shares Metastatic cancer (cancer that has spread) and the tag owner-request.
Shares Stereotactic ablative radiotherapy for oligometastatic disease, SBRT / SABR (stereotactic radiotherapy), Metastatic cancer (cancer that has spread), Prostate cancer.
Shares SBRT / SABR (stereotactic radiotherapy), HR-positive / HER2-negative breast cancer, Prostate cancer, Non-small-cell lung cancer.
Shares ORIOLE, STOMP, SBRT / SABR (stereotactic radiotherapy), Metastatic cancer (cancer that has spread).
Shares SBRT / SABR (stereotactic radiotherapy), Lung cancer (all types), Non-small-cell lung cancer.
Shares Stereotactic ablative radiotherapy for oligometastatic disease, SBRT / SABR (stereotactic radiotherapy), Metastatic cancer (cancer that has spread), Prostate cancer.
Shares SBRT / SABR (stereotactic radiotherapy), HR-positive / HER2-negative breast cancer, Prostate cancer, Colorectal cancer.